MRTX — Mirati Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- $4.12bn
- $3.15bn
- $12.44m
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 223 | 415 | 1,390 | 1,491 | 1,084 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.768 | 1.57 | 2.3 | 2.51 | 3.73 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 227 | 424 | 1,404 | 1,508 | 1,109 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.473 | 2.38 | 47.7 | 53.5 | 53.7 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 228 | 432 | 1,476 | 1,589 | 1,203 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 26.1 | 48.9 | 71.5 | 144 | 159 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 26.9 | 49.9 | 115 | 192 | 206 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 202 | 382 | 1,361 | 1,397 | 997 |
Total Liabilities & Shareholders' Equity | 228 | 432 | 1,476 | 1,589 | 1,203 |
Total Common Shares Outstanding |